CTOs on the Move

Biometrica Systems Inc

www.biometrica.com

 
Biometrica Systems Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Las Vegas, NV. To find more information about Biometrica Systems Inc, please visit www.biometrica.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.biometrica.com
  • 750 E Warm Springs Rd Ste 240
    Las Vegas, NV USA 89119-4383
  • Phone: 702.870.6949

Executives

Name Title Contact Details

Similar Companies

Prince Agri Products

Prince Agri Products is a Quincy, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ClinX

Clin-X, comprised of three affiliated companies (ClinEdge, BTC Network, and GuideStar Research), provides a full range of clinical and outsourced business services to clinical research institutions, hospitals, pharmaceutical companies, and CROs. Combined, the companies represent four business segments: two global networks of research clinics, consulting and financial management, and patient recruitment and retention. The business segments seamlessly work together to streamline research operations, minimize enrollment timelines, and overall help research institution businesses thrive.

Ameronc Inc

Ameronc Inc is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Columbus Regional Healthcare System

Columbus Regional Healthcare System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Columbus Regional Healthcare System is based in Whiteville, NC. You can find more information on Columbus Regional Healthcare System at www.crhealthcare.org

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.